



ASX and Media Release

18 March 2019

Opthea Added to the S&P/ASX All Ordinaries Index

Melbourne, Australia; 18 Mar 2019 – Opthea Limited (ASX:OPT) a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, is pleased to announce that the Company will be added to the S&P/ASX All Ordinaries Index, effective upon market open on Monday, March 18, 2019.

The S&P/ASX family of indices measures the performance of ASX-listed companies across various sizes, industries, themes and strategies. Each index is designed to represent a certain segment of the Australian equities market. The S&P/ASX All Ordinaries Index which is rebalanced annually, measures the performance of the total Australian equity market and is composed of the 500 largest securities listed on the ASX.

“Addition to the S&P/ASX All Ordinaries Index provides greater market visibility for Opthea and its clinical programs in wet age-related macular degeneration and diabetic macular edema, which could ultimately result in a broader shareholder base for the Company,” said Dr Megan Baldwin, CEO and Managing Director of Opthea.

For more information about the S&P/ASX All Ordinaries Index visit:

<https://au.spindices.com/indices/equity/all-ordinaries>

About Opthea Limited

Opthea (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. Opthea's lead asset is OPT-302, a 'trap' inhibitor of VEGF-C and VEGF-D, being developed as a complementary medicine to be used in conjunction with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 in wet AMD patients and has two ongoing Phase 2 clinical trials in wet AMD and DME respectively. Opthea's technology is based on extensive intellectual property related to VEGF-C, VEGF-D and VEGFR-3 that is held in Opthea's 100% owned subsidiary Vegenics Pty Ltd.

Additional information on Opthea's technology and clinical trials in wet AMD and DME can be found at www.opthea.com and ClinicalTrials.gov (ID#: NCT03345082 and ID#: NCT03397264, respectively).

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Forward-looking statements

Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Opthea undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.

Company & Media Enquiries:

Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 447 788 674
megan.baldwin@opthea.com

Australia:
Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com

U.S.A. & International:

Jason Wong
Blueprint Life Science Group
Tel: +1 415 375 3340, Ext 4
Jwong@bplifescience.com